Schwarzenberger Claudia, Sradnick Jan, Lerea Kenneth M, Goligorsky Michael S, Nieswandt Bernhard, Hugo Christian P M, Hohenstein Bernd
Division of Nephrology, Department of Internal Medicine III, Technische Universitaet Dresden, Dresden, Germany;
Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York;
Am J Physiol Renal Physiol. 2015 Jun 1;308(11):F1238-46. doi: 10.1152/ajprenal.00535.2014. Epub 2015 Apr 1.
Several studies have suggested a prominent (pro)inflammatory and harmful role of platelets in renal disease, and newer work has also demonstrated platelet release of proangiogenic factors. In the present study, we investigated the role of platelets in a mouse model of selective endothelial cell injury using either platelet depletion or the pharmacological P2Y12 receptor blocker clopidogrel as an interventional strategy. The concanavalin A/anti-concanavalin A model was induced in left kidneys of C57bl/6J wild-type mice after initial platelet depletion or platelet-inhibiting therapy using clopidogrel. FACS analysis of glycoprotein IIb/IIIa/P-selectin double-positive platelets and platelet-derived microparticles demonstrated relevant platelet activation after the induction of selective endothelial injury in mice. Enhanced platelet activation persisted for 5 days after disease induction and was accompanied by increased amounts of circulating platelet-derived microparticles as potential mediators of a prolonged procoagulant state. By immunohistochemistry, we detected significantly reduced glomerular injury in platelet-depleted mice compared with control mice. In parallel, we also saw reduced endothelial loss and a consequently reduced repair response as indicated by diminished proliferative activity. The P2Y12 receptor blocker clopidogrel demonstrated efficacy in limiting platelet activation and subsequent endothelial injury in this mouse model of renal microvascular injury. In conclusion, platelets are relevant mediators of renal injury induced by primary endothelial lesions early on, as demonstrated by platelet depletion as well as platelet inhibition via the P2Y12 receptor. While strategies to prevent platelet-endothelial interactions have shown protective effects, the contribution of platelets during renal regeneration remains unknown.
多项研究表明血小板在肾脏疾病中具有显著的(促)炎和有害作用,并且新的研究还证实了血小板可释放促血管生成因子。在本研究中,我们使用血小板耗竭或药理学P2Y12受体阻滞剂氯吡格雷作为干预策略,研究了血小板在选择性内皮细胞损伤小鼠模型中的作用。在最初进行血小板耗竭或使用氯吡格雷进行血小板抑制治疗后,在C57bl/6J野生型小鼠的左肾中诱导刀豆球蛋白A/抗刀豆球蛋白A模型。对糖蛋白IIb/IIIa/P-选择素双阳性血小板和血小板衍生微粒进行流式细胞术分析,结果表明在小鼠诱导选择性内皮损伤后血小板发生了相关激活。疾病诱导后,血小板激活增强持续了5天,并伴有循环中血小板衍生微粒数量增加,这些微粒可能是延长的促凝状态的介质。通过免疫组织化学,我们检测到与对照小鼠相比,血小板耗竭小鼠的肾小球损伤明显减轻。同时,我们还观察到内皮细胞损失减少,增殖活性降低表明修复反应也随之减少。在这个肾微血管损伤小鼠模型中,P2Y12受体阻滞剂氯吡格雷在限制血小板激活和随后的内皮损伤方面显示出疗效。总之,正如血小板耗竭以及通过P2Y12受体抑制血小板所表明的那样,血小板是早期原发性内皮损伤诱导的肾损伤的相关介质。虽然预防血小板-内皮细胞相互作用的策略已显示出保护作用,但血小板在肾脏再生过程中的作用仍不清楚。